Skip to main content
SpringerLink
Log in

Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung

  • Original Articles
  • Mitomycin C, Non-Oat Cell Lung Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The disposition kinetics of the cancer chemotherapeutic agent mitomycin C have been studied in six male patients receiving mitomycin C in combination with cisplatin and vinblastine for non-oat cell carcinoma of the lung. Following rapid IV administration of mitomycin C (10 mg/m2), serum concentration-time course data were biexponential, with biologic half-lives of 46.2 ± 12.1 min (mean ± SD). Pharmacokinetic analysis of data by the CSTRIP and NONLIN digital computer programs generated parameters which suggested extensive distribution (Varea=656.8±169.8 ml·kg−1, mean ±SD) and, as reported for other alkylating agents, rapid elimination (total body clearance=10.3 ± 3.2 ml · kg−1 · min−1, mean ± SD). Interpatient variations in pharmacokinetic parameters were relatively small, suggesting that close monitoring of mitomycin C therapy might be unnecessary in patients with normal renal and hepatic function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Buice RG, Sidhu P, Gurley BJ, Niell HB (1983) Reversed-phase high performance liquid chromatographic determination of mitomycin C in human serum. Ther Drug Monit (in press)

  2. Butler TP, MacDonald JS, Smith FP, Smith LF, Woolley PV, Schein PS (1979) 5-Fluorouracil, adriamycin, and mitomycin C (FAM) chemotherapy for adenocarcinoma of the lung. Cancer 43:1183

    PubMed  Google Scholar 

  3. Carr DT, Mountain CF (1974) The staging of lung cancer. Semin Oncol 1:229

    PubMed  Google Scholar 

  4. Den Hartigh J, Van Oort WJ (1981) High performance liquid chromatographic determination of the antitumor agent mitomycin C in human blood plasma. Anal Chim Acta 127:47

    Article  Google Scholar 

  5. Edwards D, Selkirk AB, Taylor RB (1979) Determination of the stability of mitomycin C by high performance liquid chromatography. Int J Pharm 4:21

    Article  Google Scholar 

  6. Ferguson D, Humphrey E (1960) Mitomycin C. Cancer Chemother Rep 8:154

    Google Scholar 

  7. Frank W, Osterberg AE (1960) Mitomycin C (NSC-26980): An evaluation of the Japanese reports. Cancer Chemother Rep 9:114

    PubMed  Google Scholar 

  8. Jujita H (1971) Comparative studies on the blood level, tissue distribution, excretion and inactivation of anticancer drugs. Jpn J Clin Oncol 12:151

    Google Scholar 

  9. Godfrey TE, Wilbur DW (1972) Clinical experience with mitomycin C in large infrequent doses. Cancer 29:1647

    PubMed  Google Scholar 

  10. Jones R (1959) Mitomycin C: A preliminary report of studies of human pharmacology and initial therapeutic trial. Cancer Chemother Rep 2:3

    Google Scholar 

  11. Karnoksky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM (ed) Evaluation of chemotherapeutic agents. Symposium, Microbiology Section, New York Academy of Medicine, Columbia University Press, New York, p 191

    Google Scholar 

  12. Kono A, Hara Y, Eguchi S, Tanaka M (1979) Determination of mitomycin C in biomedical specimens by high-performance liquid chromatography. J Chromatogr 164:404

    PubMed  Google Scholar 

  13. Metzler CM (1974) NONLIN: A computer program for parameter estimation in nonlinear situations. Users Manual, The Upjohn Company, Kalamazoo MI 49001

    Google Scholar 

  14. Miller TP, McMahon LJ, Livingston RB (1980) Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FV, vincristine and mitomycin C (FOMi) Cancer Treat Rep 64:1241

    PubMed  Google Scholar 

  15. Niell HB, Griffin JP, West WH, Neely CL (1983) Combination chemotherapy with mitomycin C, methotrexate, cisplatin, and vinblastine in the treatment of non-small cell lung cancer. Cancer (in press)

  16. Reich SD (1979) Clinical pharmacology of mitomycin C. In: Carter SK, Crooke ST (eds) Mitomycin C: Current status and new developments. Academic Press, London, p 243

    Google Scholar 

  17. Samson MK, Comis RL, Baker LH, Ginsberg S, Fraile RJ, Crooke ST (1978) Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 62:163

    PubMed  Google Scholar 

  18. Schwartz HS (1961) Pharmacology of mitomycin C. III. In vivo metabolism by rat liver. J Pharmacol Exp Ther 136:250

    Google Scholar 

  19. Schwartz HS, Philips FS (1961) Pharmacology of mitomycin C. II. Renal excretion and metabolism by tissue homogenates. J Pharmacol Exp Ther 133:335

    PubMed  Google Scholar 

  20. Sedman AJ, Wagner JG (1976) CSTRIP, A FORTRAN IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 65:1006

    PubMed  Google Scholar 

  21. Srivastava SC, Hornemann U (1978) High pressure liquid chromatography of the antibiotics mitomycin A, B, and C and of polar mitomycin C conversion products. J Chromatogr 161:393

    Article  Google Scholar 

  22. Sutow WW, Wilbur JR, Viett TJ, Vuthibhagdee P, Fujimoto T, Wantanabe A (1971) Evaluation of dosage schedule of mitomycin C (NSC-26980). Cancer Chemother Rep 55:285

    PubMed  Google Scholar 

  23. Tjader UR, Langenberg JP, Ensing K, Van Bennekom WP, De Bruijn EA, Van Oosterom AT (1982) Determination of mitomycin C in plasmma, serum, and urine by high-performance liquid chromatography with ultraviolet and electrochemical detection. J Chromatogr 232:355

    PubMed  Google Scholar 

  24. Van der Mere AM, Falkson HC, Falkson G (1971) Clinical experience with mitomycin C (NSC-26980) in malignant disease. Med Proc 17:90

    Google Scholar 

  25. Van Hazel GA, Kovach JS (1982) Pharmacokinetics of mitomycin C in rabbit and human. Cancer Chemother Pharmacol 8:189

    Article  PubMed  Google Scholar 

  26. Wagner JG (1976) Linear pharmacokinetic equations allowing for direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm 4:443

    PubMed  Google Scholar 

  27. Wakaki S, Marumo H, Tamioka K, Shimizu G, Kato E, Kamada H, Kudo S, Fujimoto Y (1958) Isolations of new fractions of antitumor mitomycins. Antibiot Chemother 8:228

    Google Scholar 

  28. Whittington RM, Close HP (1970) Clinical experience with mitomycin C (NSC-26980). Cancer Chemother Rep 54:195

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, University of Tennessee Center for the Health Sciences, 874 Union Avenue, 38163, Memphis, TN, USA

    Robert G. Buice, P. Sidhu & B. J. Gurley

  2. Department of Medicine, University of Tennessee Center for the Health Sciences, 874 Union Avenue, 38163, Memphis, TN, USA

    Harvey B. Niell

Authors
  1. Robert G. Buice
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harvey B. Niell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Sidhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. J. Gurley
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buice, R.G., Niell, H.B., Sidhu, P. et al. Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung. Cancer Chemother. Pharmacol. 13, 1–4 (1984). https://doi.org/10.1007/BF00401436

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00401436

Keywords

Search

Navigation